The Journal of Allergy and Clinical Immunology
Volume 119, Issue 6 , Pages 1291-1300 , June 2007

Eosinophilic disorders

  • Dagmar Simon, MD

      Affiliations

    • From the Departments of Dermatology, Inselspital
    • ,
  • Hans-Uwe Simon, MD, PhD

      Affiliations

    • Pharmacology, University of Bern
    • Corresponding Author InformationReprint requests: Hans-Uwe Simon, MD, PhD, Department of Pharmacology, University of Bern, Friedbühlstrasse 49, CH-3010 Bern, Switzerland.

Received 15 January 2007 ,Revised 12 February 2007 ,Accepted 13 February 2007.

References 

  1. Osgood EE, Brownlee IE, Osgood MW, Ellis DM, Cohen W. Total differential and absolute leukocyte counts and sedimentation rates. Arch Int Med. 1939;64:105–120
  2. Straumann A, Simon HU. The physiological and pathophysiological roles of eosinophils in the gastrointestinal tract. Allergy. 2004;59:15–25
  3. McMaster MT, Newton RC, Dey SK, Andrews GK. Activation and distribution of inflammatory cells in the mouse uterus during the preimplantation period. J Immunol. 1992;148:1699–1705
  4. Robertson SA, Mau VJ, Hudson SA, Tremellen KP. Cytokine-leukocyte networks and the establishment of pregnancy in the mouse. J Reprod Fertil. 1997;107:265–277
  5. Gouon-Evans V, Rothenberg ME, Pollard JW. Postnatal mammary gland development requires macrophages and eosinophils. Development. 2000;127:2269–2282
  6. Ehrlich P. Beiträge zur Kenntnis der granulierenden Bindegewebszellen und der eosinophilen Leukocyten. Arch Anat Physiol. 1879;166–169
  7. Bain B, Pierre R, Imbert M, Vardiman JW, Brunning RD, Flandrin G. Chronic eosinophilic leukaemia and the hypereosinophilic syndrome. In:  Jaffe ES,  Harris NL,  Stein H,  Vardiman JW editor. World Health Organization classification of tumours: pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001;p. 29–31
  8. Ollendorff V, Guasch G, Isnardon D, Galindo R, Birnbaum D, Pebusque MJ. Characterization of FIM-FGFR I, the fusion product of the myeloproliferative disorder-associated t(8;13) translocation. J Biol Chem. 1999;274:26922–26930
  9. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, et al. A tyrosine kinase created by the fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201–1214
  10. Gotlib J, Cross NCP, Gilliland DG. Eosinophilic disorders: molecular pathogenesis, new classification, and modern therapy. Best Pract Res Clin Haematol. 2006;3:535–569
  11. Bain BJ. Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis. Am J Haematol. 2004;77:82–85
  12. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukemias. Br J Haematol. 2003;122:173–179
  13. Spiers ASD, Bain BJ, Turner JE. The peripheral blood in chronic granulocytic leukaemia. Scand J Haematol. 1977;18:25–38
  14. Keung YK, Beaty M, Steward W, Jackle B, Pettnati M. Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13) and ETV6-ABL gene rearrangement: case report and review of the literature. Cancer Genet Cytogenet. 2002;138:139–142
  15. Reiter A, Walz C, Watmore A, Schoch C, Blau I, Schlegelberger B, et al. The t(8;9)(p22;p24) is a recurrent abnormality in chronic and acute leukemia that fuses PCMI to Jak2. Cancer Res. 2005;65:2662–2667
  16. Simon HU, Yousefi S, Dibbert B, Levi-Schaffer F, Blaser K. Anti-apoptotic signals of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophils. Eur J Immunol. 1997;27:3536–3539
  17. Steensma DP, Tefferi A. The myelodysplastic syndrome(s): a perspective and review highlighting current controversies. Leuk Res. 2003;27:95–120
  18. Ma SK, Wong KF, Chan JK, Kwong YL. Refractory cytopenia with t(1;7),+8 abnormality and dysplastic eosinophils showing intranuclear Charcot-Leyden crystals: a fluorescence in situ hybridization study. Br J Haematol. 1995;90:216–218
  19. Imai Y, Yasuhara S, Hanafusa N, Ohsaka A, Enokihara H, Tomizuka H, et al. Clonal involvement of eosinophils in therapy-related myelodysplastic syndrome with eosinophilia, translocation t(1;7) and lung cancer. Br J Haematol. 1996;95:710–714
  20. Ying S, Durham SR, Barkans J, Masuyama K, Jacobson M, Rak S, et al. T cells are the principal source of interleukin-5 mRNA in allergen-induced rhinitis. Am J Respir Cell Mol Biol. 1993;9:356–360
  21. Robinson DS, Hamid Q, Ying S, Tsicopoulos A, Barkans J, Bentley AM, et al. Predominant Th2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med. 1992;326:298–304
  22. Straumann A, Bauer M, Fischer B, Blaser K, Simon HU. Idiopathic eosinophilic esophagitis is associated with a Th2-type allergic inflammatory response. J Allergy Clin Immunol. 2001;108:954–961
  23. Simon D, Vassina E, Yousefi S, Kozlowski E, Braathen LR, Simon HU. Reduced dermal infiltration of cytokine-expressing inflammatory cells in atopic dermatitis after short-term topical tacrolimus treatment. J Allergy Clin Immunol. 2004;114:887–895
  24. Rothenberg ME. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol. 2004;113:11–28
  25. Cay A, Imamoglu M, Cobanoglu U. Eosinophil pancreatitis mimicking pancreatic neoplasia. Can J Gastroenterol. 2006;20:361–364
  26. Hill SM, Milla PJ. Colitis caused by food allergy in infants. Arch Dis Child. 1990;65:132–133
  27. Bousquet J, Chanez P, Lacoste JY, Barnéon G, Ghavanian N, Enander I, et al. Eosinophilic inflammation in asthma. N Engl J Med. 1990;323:1033–1039
  28. Sanderson CJ. Interleukin-5, eosinophils, and disease. Blood. 1992;79:3101–3109
  29. Rothenberg ME, Hogan SP. The eosinophil. Ann Rev Immunol. 2006;24:147–174
  30. Kay AB, Phipps S, Robinson D. A role for eosinophils in airway remodelling in asthma. Trends Immunol. 2004;25:477–482
  31. Lecki MJ, ten Brinke A, Khan J, Diamant Z, O'Connor BJ, Walls CM, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet. 2000;356:2144–2148
  32. Kips JC, O'Connor BJ, Langley SJ, Woodcock A, Kerstjens HA, Postma DS, et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am J Respir Crit Care Med. 2003;167:1655–1659
  33. Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil's role remains uncertain as anti-IL-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167:199–204
  34. Buttner C, Lun A, Splettstoesser T, Kunkel G, Renz H. Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T cell function. Eur Respir J. 2003;21:799–803
  35. Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:693–696
  36. Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, van Zele T, et al. Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps. J Allergy Clin Immunol. 2006;118:1133–1141
  37. Stein ML, Collins MH, Villanueva JM, Kushner JP, Putnam PE, Buckmeier BK, et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J Allergy Clin Immunol. 2006;118:1312–1319
  38. Guillevin L, Cohen P, Gayraud M, Lhote F, Jarrousse B, Casassus P. Churg-Strauss syndrome: clinical study and long-term follow-up of 96 patients. Medicine (Baltimore). 1999;78:26–37
  39. Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol. 2002;110:685–692
  40. Meningaud JP, Pitak-Arnnop P, Fouret P, Bertrand JC. Kimura's disease of the parotid region: report of 2 cases and review of the literature. J Oral Maxillofac Surg. 2007;65:134–140
  41. Jederlinic PJ, Sicilian L, Gaensler EA. Chronic eosinophilic pneumonia: a report of 19 cases and a review of the literature. Medicine (Baltimore). 1988;67:154–162
  42. Walker C, Bode E, Boer L, Hansel TT, Blaser K, Virchow JC. Allergic and nonallergic asthmatics have distinct patterns of T-cell activation and cytokine production in peripheral blood and bronchoalveolar lavage. Am Rev Respir Dis. 1992;146:109–115
  43. Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K. Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol. 1997;158:3902–3908
  44. Akdis CA, Akdis M, Simon D, Dibbert B, Weber M, Gratzl S, et al. T cells and T cell-derived cytokines as pathogenic factors in the nonallergic form of atopic dermatitis. J Invest Dermatol. 1999;113:628–634
  45. Cox D, Earle L, Jimenez SA, Leiferman KM, Gleich GJ, Varga J. Elevated levels of eosinophil major basic protein in the sera of patients with systemic sclerosis. Arthritis Rheum. 1996;38:939–945
  46. Viallard JF, Taupin JL, Ranchin V, Leng B, Pellegrin JL, Moreau JF. Analysis of leukemia inhibitory factor, type 1 and type 2 cytokine production in patients with eosinophilic fasciitis. J Rheumatol. 2001;28:75–80
  47. Yamazaki K, Nakadate I, Suzuki K, Sato S, Masuda T. Eosinophilia in primary biliary cirrhosis. Am J Gastroenterol. 1996;91:516–522
  48. Nagano T, Yamamoto K, Matsumoto S, Okamoto R, Tagashira M, Ibuki N, et al. Cytokine profile in the liver of primary biliary cirrhosis. J Clin Immunol. 1999;19:422–427
  49. Heufelder AE, Goellner JR, Bahn RS, Gleich GJ, Hay ID. Tissue eosinophilia and eosinophil degranulation in Riedel's invasive fibrous thyroiditis. J Clin Endocrinol Metab. 1996;81:977–984
  50. Kargi A, Bavbek N, Kaya A, Kosar A, Karaaslan Y. Eosinophilia in rheumatologic diseases: a prospective study of 100 cases. Rheumatol Int. 2004;24:321–324
  51. Wakugawa M, Nakamura K, Hino H, Toyama K, Hattori N, Okochi H, et al. Elevated levels of eotaxin and interleukin-5 in blister fluid of bullous pemphigoid: correlation with tissue eosinophilia. Br J Dermatol. 2000;143:112–116
  52. Eriksson MO, Hagforsen E, Lundin IP, Michaelsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390–398
  53. Rasi A, Khatami A. Autoimmune progesterone dermatitis. Int J Dermatol. 2004;43:588–590
  54. Klion AD, Nutman TB. The role of eosinophils in host defense against helminth parasites. J Allergy Clin Immunol. 2004;113:30–37
  55. Sturrock RF, Kimani R, Cottrell BJ, Butterworth AE, Seitz HM, Siongok TK, et al. Observations on possible immunity to reinfection among Kenyan schoolchildren after treatment for Schistosoma mansoni. Trans R Soc Trop Med Hyg. 1983;77:363–371
  56. Coffman RL, Seymour BW, Hudak S, Jackson J, Rennick D. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science. 1989;245:308–310
  57. MacDonald SM, Bhisutthibhan J, Shapiro TA, Rogerson SJ, Taylor TE, Tembo M, et al. Immune mimicry in malaria: Plasmodium falciparum secretes a functional histamine-releasing factor homolog in vitro and in vivo. Proc Natl Acad Sci U S A. 2001;98:10829–10832
  58. Ansarin H, Jalali MH, Mazloomi S, Soltani-Arabshahi R, Setarehshenas R. Scabies presenting with bullous pemphigoid-like lesions. Dermatol Online J. 2006;12:19
  59. Wood C, Miller AC, Jacobs A, Hart R, Nickoloff BJ. Eosinophilic infiltration with flame figures: a distinctive tissue reaction seen in Wells' syndrome and other diseases. Am J Dermatopathol. 1986;8:186–193
  60. Lehrer RI, Szklarek D, Barton A, Ganz T, Hamann KJ, Gleich GJ. Anti-bacterial properties of eosinophil major basic protein (MBP) and eosinophil cationic protein (ECP). J Immunol. 1989;142:4428–4434
  61. Plötz SG, Lentschat A, Behrendt H, Plötz W, Hamann L, Ring J, et al. The interaction of human peripheral blood eosinophils with bacterial lipopolysaccharide is CD14 dependent. Blood. 2001;97:235–241
  62. Zhang N, Gevaert P, van Zele T, Perez-Novo C, Patou J, Holtappels G, et al. An update on the impact of Staphylococcus aureus enterotoxins in chronic sinusitis with nasal polyposis. Rhinology. 2005;43:162–168
  63. Cardona ID, Cho SH, Leung DY. Role of bacterial superantigens in atopic dermatitis: implications for future therapeutic strategies. Am J Clin Dermatol. 2006;7:273–279
  64. Yousem SA. Graft eosinophilia in lung transplantation. Hum Pathol. 1992;23:1172–1177
  65. Berger BW, Clemmensen OJ, Ackerman AB. Lyme disease is a spirochetosis: a review of the disease and evidence for its cause. Am J Dermatopathol. 1983;5:111–124
  66. Granter SR, Barnhill RL, Hewins ME, Duray PH. Identification of Borrelia burgdorferi in diffuse fasciitis with peripheral eosinophilia: borrelial fasciitis. JAMA. 1994;272:1283–1285
  67. Papi A, Luppi F, Franco F, Fabbri LM. Pathophysiology of exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006;3:245–251
  68. Coyle AJ, Erard F, Bertrand C, Walti S, Pircher H, Le Gros G. Virus-specific CD8+ cells can switch to interleukin 5 production and induce airway eosinophilia. J Exp Med. 1995;181:1229–1233
  69. Busse WW, Gern JE. Viruses in asthma. J Allergy Clin Immunol. 1997;100:147–150
  70. Becker Y. Respiratory syncytial virus (RSV) evades the human adaptive immune system by skewing the Th1/Th2 cytokine balance toward increased levels of Th2 cytokines and IgE, markers of allergy: a review. Virus Genes. 2006;33:235–252
  71. Slifman NR, Loegering DA, McKean DJ, Gleich GJ. Ribonuclease activity associated with human eosinophil-derived neurotoxin and eosinophil cationic protein. J Immunol. 1986;137:2913–2917
  72. Clerici M, Shearer GM. A Th1->Th2 switch is a critical step in the etiology of HIV infection. Immunol Today. 1993;14:107–111
  73. Whittaker SJ, Ng YL, Rustin M, Levene G, McGibbon DH, Smith NP. HTLV-1-associated cutaneous disease: a clinicopathological and molecular study of patients from U.K. Br J Dermatol. 1993;128:483–492
  74. Sasama J, Sherris DA, Shin SH, Kephart GM, Kern EB, Ponikau JU. New paradigm for the roles of fungi and eosinophils in chronic rhinosinusitis. Curr Opin Otolaryngol Head Neck Surg. 2005;13:2–8
  75. Shin SH, Ponikau JU, Sherris DA, Congdon D, Frigas E, Homburger HA, et al. Rhinosinusitis: an enhanced immune response to ubiquitous airborne fungi. J Allergy Clin Immunol. 2004;114:1369–1375
  76. Fischer Casagrande B, Flückiger S, Tengvall Linder M, Johansson C, Scheynius A, Crameri R, et al. Sensitization to the yeast Malassezia sympodialis is specific for extrinsic and intrinsic atopic eczema. J Invest Dermatol. 2006;126:2414–2421
  77. Schaffer JV. The changing face of graft-versus-host disease. Semin Cutan Med Surg. 2006;25:190–200
  78. Janin A, Socie G, Devergia A, Aractingi S, Esperou H, Verola O, et al. Fasciitis in chronic graft-versus-host disease: a clinicopathologic study of 14 cases. Ann Intern Med. 1994;120:993–998
  79. Jacobsohn DA, Schechter T, Seshadri R, Thormann K, Duerst R, Kletzel M. Eosinophilia correlates with the presence or development of chronic graft-versus-host disease in children. Transplantation. 2004;77:1096–1100
  80. Basara N, Kiehl MG, Fauser AA. Eosinophilia indicates the evolution to acute graft-versus-host disease. Blood. 2002;100:3055
  81. Aleman K, Noordzij JG, de Groot R, van Dongen JJM, Hartwig NG. Reviewing Omenn syndrome. Eur J Pediatr. 2001;160:718–725
  82. Grimbacher B, Holland SM, Gallin JI, Greenberg F, Hill SC, Malech HL, et al. Hyper-IgE syndrome with recurrent infections: an autosomal dominant multisystem disorder. N Engl J Med. 1999;340:692–702
  83. Simon HU, Seger R. Hyper-IgE syndrome associated with an IL-4–producing γ/δ+ T-cell clone. J Allergy Clin Immunol. 2007;119:246–248
  84. Jaggi P, Freeman AF, Katz BZ. Chronic granulomatous disease presenting with eosinophilic inflammation. Pediatr Infect Dis J. 2005;24:1020–1021
  85. Jezior D, Boratynska M, Halon A, Kusztal M, Rabczynski J, Szyber P, et al. Biopsy eosinophilia as a predictor of renal graft dysfunction. Transplant Proc. 2003;35:2182–2185
  86. Meleg-Smith S, Gauthier PM. Abundance of interstitial eosinophils in renal allografts is associated with vascular rejection. Transplantation. 2005;79:444–450
  87. Wolff D, Steiner B, Stilgenbauer S, Kahl C, Leithauser M, Junghanss C, et al. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD. Eur J Haematol. 2004;72:145–148
  88. Simon HU, Plötz SG, Dummer R, Blaser K. Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med. 1999;341:1112–1120
  89. Cogan E, Schandené L, Crusiaux A, Cochaux P, Velu T, Goldman M. Brief report: clonal proliferation of type 2 helper T cells in a man with the hypereosinophilic syndrome. N Engl J Med. 1994;330:535–538
  90. Simon HU, Yousefi S, Dommann-Scherrer CC, Zimmermann DR, Bauer S, Barandun J, et al. Expansion of cytokine-producing CD4-CD8-T cells associated with abnormal Fas expression and hypereosinophilia. J Exp Med. 1996;183:1071–1082
  91. Simon HU, Plötz SG, Simon D, Dummer R, Blaser K. Clinical and immunological features of patients with interleukin-5-producing T cell clones and eosinophilia. Int Arch Allergy Immunol. 2001;124:242–245
  92. Klion AD, Bochner BS, Gleich GJ, Nutman TB, Rothenberg ME, Simon HU, et al. Approaches to the treatment of hypereosinophilic syndromes: a workshop summary report. J Allergy Clin Immunol. 2006;117:1292–1302
  93. Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology. 2005;209:123–129
  94. Wolf R, Matz H, Marcos B, Orion E. Drug rush with eosinophilia and systemic symptoms vs toxic epidermal necrolysis: the dilemma of classification. Clin Dermatol. 2005;23:311–314
  95. Pichler WJ. Pharmacological interaction of drugs with antigen-specific immune responses: the p-i concept. Curr Opin Allergy Clin Immunol. 2002;2:301–305
  96. Pichler WJ. Direct T-cell stimulations by drugs: bypassing the innate immune system. Toxicology. 2005;209:95–100
  97. Dicker RM, James N, Cunha BA. The eosinophilia-myalgia syndrome with neuritis associated with L-tryptophan use. Ann Intern Med. 1990;112:957–958
  98. Rigau-Perez JG, Perez-Alvarez L, Duenas-Castro S, Choi K, Thacker SB, Germain JL, et al. Epidemiologic investigation of an oil-associated pneumonic paralytic eosinophilic syndrome in Spain. Am J Epidemiol. 1984;119:250–260
  99. Owen WF, Petersen J, Sheff DM, Folkerth RD, Anderson RJ, Corson JM, et al. Hypodense eosinophils and interleukin-5 activity in the blood of patients with eosinophilia-myalgia syndrome. Proc Natl Acad Sci U S A. 1990;87:8647–8651
  100. Nagai Y, Mori T, Abe T, Nomura G. Immediate-type allergy against human insulin associated with marked eosinophilia in type 2 diabetic patient. Endocr J. 2001;48:311–316
  101. Silberstein DS, Schoof DD, Rodrick ML, Tai PC, Spry CJ, Davis JR, et al. Activation of eosinophils in cancer patients treated with interleukin-2 and interleukin-2-generated LAK cells. J Immunol. 1989;142:2162–2167
  102. Groopman JE, Mitsuyasu RT, DeLeo MJ, Oette DH, Golde DW. Effect of recombinant human granulocyte-macrophage colony-stimulating factor on myelopoiesis in the acquired immunodeficiency syndrome. N Engl J Med. 1987;317:593–599
  103. Chan JL, Davis-Reed L, Kimball AB. Counter regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. J Drugs Dermatol. 2004;3:315–318
  104. Bonnekoh B, Schulz M, Franke I, Gollnick H. Complete remission of a primary cutaneous B-cell lymphoma of the lower leg by first-line monotherapy with the anti-CD20-antibody rituximab. J Cancer Res Clin Oncol. 2002;128:161–166
  105. Plötz SG, Simon HU, Darsow U, Simon D, Vassina E, Yousefi S, et al. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis. N Engl J Med. 2003;349:2334–2339
  106. Butterfield JH, Leiferman KM, Abrams J, Silver JE, Bower J, Gonchoroff N, et al. Elevated serum levels of interleukin-5 in patients with the syndrome of episodic angioedema and eosinophilia. Blood. 1992;79:688–692
  107. Rioux JD, Stone VA, Daly MJ, Cargill M, Green T, Nguyen H, et al. Familial eosinophilia maps to the cytokine gene cluster on human chromosomal region 5Q31-q33. Am J Hum Genet. 1998;63:1086–1094
  108. Gruss HJ, Herrmann F, Drexler HG. Hodgkin's disease: a cytokine- producing tumor: a review. Crit Rev Oncogenesis. 1994;5:473–538
  109. Ionescu MA, Rivet J, Daneshpouy M, Briere J, Morel P, Janin A. In situ eosinophil activation in 26 primary cutaneous T-cell lymphomas with blood eosinophilia. J Am Acad Dermatol. 2005;52:32–39
  110. Borish L, Dishuck J, Cox L, Mascali JJ, Williams J, Rosenwasser LJ. Sezary syndrome with elevated IgE and hypereosinophilia: role of dysregulated cytokine production. J Allergy Clin Immunol. 1993;92:123–131
  111. Tono-oka T, Sato Y, Matsumoto T, Ueno N, Ohkawa M, Shikano T, et al. Hypereosinophilic syndrome in acute lymphoblastic leukemia with a chromosomal translocation [t(5q;14q)]. Med Pediatr Oncol. 1984;12:33–37
  112. Hogan TF, Koss W, Murgo AJ, Amato RS, Fontana JA, VanScoy FL. Acute lymphoblastic leukemia with chromosomal 5:14 translocation and hypereosinophilia: case report and literature review. J Clin Oncol. 1987;5:382–390
  113. Meeker TC, Hardy D, Willman C, Hogan T, Abrams J. Activation of the interleukin-3 gene by chromosome translocation in acute lymphocytic leukemia with eosinophilia. Blood. 1990;76:285–289
  114. Laman JD, Leenen PJM, Annels NE, Hogendoorn PCW. Egeler RM. Langerhans-cell histiocytosis “insight into DC biology.”. Trends Immunol. 2003;24:190–196
  115. Lowe D, Jorizzo J, Hutt MSR. Tumour-associated eosinophilia: a review. J Clin Pathol. 1981;34:1343–1348
  116. Geisinger KR, Steffee CH, McGee RS, Woodruff RD, Buss DH. The cytomorphologic features of sclerosing mucoepidermoid carcinoma of the thyroid gland with eosinophilia. Am J Clin Pathol. 1998;109:294–301
  117. Horie S, Okubo Y, Suzuki J, Isobe M. An emaciated man with eosinophilic pneumonia. Lancet. 1996;348:166
  118. Fridlender ZG, Simon HU, Shalit M. Metastatic carcinoma presenting with concomitant eosinophilia and thromboembolism. Am J Med Sci. 2003;326:98–101
  119. Dibbert B, Daigle I, Braun D, Schranz C, Weber M, Blaser K, et al. Role for Bcl-xL in delayed eosinophil apoptosis mediated by granulocyte- macrophage colony-stimulating factor and interleukin-5. Blood. 1998;92:778–783
  120. Vassina EM, Yousefi S, Simon D, Zwicky C, Conus S, Simon HU. cIAP-2 and survivin contribute to cytokine-mediated delayed eosinophil apoptosis. Eur J Immunol. 2006;36:1975–1984
  121. Rothenberg ME. Eosinophilia. N Engl J Med. 1998;338:1592–1600

 (Supported by an unrestricted educational grant from Genentech, Inc. and Novartis Pharmaceuticals Corporation)Series editors: Donald Y. M. Leung, MD, PhD, and Dennis K. Ledford, MDWork in the laboratory of Dr Hans-Uwe Simon is supported by grants from the Swiss National Science Foundation (grant #310000-107526), the Stanley Thomas Johnson Foundation, Bern, and the OPO-Foundation, Zurich.Disclosure of potential conflict of interest: The authors have declared that they have no conflict of interest.

PII: S0091-6749(07)00377-6

doi: 10.1016/j.jaci.2007.02.010

The Journal of Allergy and Clinical Immunology
Volume 119, Issue 6 , Pages 1291-1300 , June 2007

Article Tools

* Image Usage & Resolution